Currently, several CLK or CLK2 inhibitors are being investigated in clinical trials for their potential use in treating various conditions such as degenerative diseases, osteoarthritis, cancers, psoriasis, scleroderma, and tendinitis (Qin et al., 2021). This evidence concerns the gene CLK2 and neurodegenerative disease.